Zoledronic Acid educates the tumor microenvironment by acting on CAFs and immune cells in breast cancer
Type: dissertation
Abstract: Zoledronic acid is an amino-bisphosphonate approved for adjuvant treatment of breast cancer, with a direct antitumor effect and an indirect anti-tumor effect by modulating the immune system.CAFs are activated fibroblasts and promote tumor development and progression and stimulate metastasis.Based on the effect of ZA on CAFs previously showed in other models, we focused our study on this component of the TME.We observed significant reduction of the tumor growth and αSMA + CAFs in 4T1 orthotopic and syngenic mouse model of 4T1 breast cancer.FACS analysis of tumors showed that ZA treatment reduced FAP + population by 79% and Tn-C + by 30% and increased PDGFRα + cells by 72% suggesting that ZA could tame CAF phenotype.We set up an autologous ex vivo in vitro system of CAFs and Tumor Infiltrating Lymphocytes (TILs) in order to investigate the crosstalk between CAFs and immune system and we excluded any cell autonomous effect of ZA on TILs and tumor cells.The observed biological effect of ZA treatment on CAFs was very strong: ZA significantly inhibited CAF migration, invasiveness and proliferation in in vitro assays.ZA indirectly affected TILs activation (IFNγ levels) when co-cultured with CAFs from ZA tumors.Moreover, treatment with ZA mediated: a reduction of pro-tumoral IL-4, IL-5, IL-6 and IL-10; an increase of anti-tumoral IL-12; a decrease of TGFβ and a decrease of TNFα.These data suggested that the treatment is able to drive CAFs to a less invasive phenotype and that ZA by acting on CAFs could impair the production of pro-tumoral IL-10 and anti-tumoral IL-12, promoting anti-tumor immune response.As consequence of enhancing INFγ expression there is a reduction of TGFβ and TNFα that could contribute to the antitumor activity.We performed similar set of experiments using a subcute mouse model of CT26 colon cancer, but data were not as compelling as in 4T1 mouse model, suggesting that the different effect of ZA could be due to the different TME of colon and breast cancer.
Author: VISINTIN, ALESSIA
Institution: University of Turin
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7217107152
